May/June 2020 Annals of Family Medicine tip sheet

What We Can Learn From Singapore’s COVID-19 Containment Response in Primary Care Singapore, a global hub for international travel and business, was among the first countries affected by the COVID-19 pandemic. With its first confirmed COVID-19 case on January 23,…

May/June 2020 Annals of Family Medicine tip sheet

What We Can Learn From Singapore’s COVID-19 Containment Response in Primary Care Singapore, a global hub for international travel and business, was among the first countries affected by the COVID-19 pandemic. With its first confirmed COVID-19 case on January 23,…

Experimental Lidocaine Derivatives May Be the Future of Postoperative Pain Control

Researchers from the University of British Columbia studied three lidocaine derivatives for use as motor blockade with promising results. This study provides insight into developing more effective, longer-lasting non-opioid local anesthetics, which could improve postoperative pain control. ASRA presented researchers with “Best of Meeting Abstract” and “Resident/Fellow Travel Award” for their work.

Labeling of cannabidiod products becoming a public health concern

New Rochelle, NY, March 25, 2020–The need for accurate and informative labeling of hemp and hemp-derived cannabidiol (CBD) products is a critical public health issue. Despite CBD being a U.S. Food and Drug Administration-approved drug, it is increasingly being added…

Health researchers find solution to life-threatening side effect

Most people know about the painkiller paracetamol, commonly used against headaches and ingested orally. However, in hospitals, paracetamol is administered intravenously. In this way, doctors and nurses can help critically ill patients who are unable to swallow one or more…

Keeping lower back pain at bay: Exercises designed by Lithuanians are 3 times more efficient

Lithuanian scientists have devised a spinal stabilization exercise program for managing lower back pain for people who perform sedentary job: Their effect lasts 3 times longer than that of a usual muscle strengthening exercise program

In NIH trial, selumetinib shrinks tumors, provides clinical benefit for children with NF1

Findings from a phase 2 clinical trial show that the drug selumetinib improves outcomes for children with the genetic disorder neurofibromatosis type 1 (NF1). In the trial, selumetinib shrank the inoperable tumors that develop with NF1 called plexiform neurofibromas, and…